Business Context and Reporting Period
Company: Rexahn Pharmaceuticals, Inc. (Note: Input metadata listed "Opus Genetics," but the filing text identifies the registrant as Rexahn Pharmaceuticals, Inc.)
Reporting Period: Quarter ended March 31, 2009
Business Stage: Development stage biopharmaceutical company focused on cancer, CNS disorders, and sexual dysfunction. The company has no commercial product sales and relies on equity financing, debt, and research contributions to fund operations.
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 | Cumulative (Inception to Mar 31, 2009) |
|---|---|---|---|
| Revenues | $18,750 | $18,750 | $468,750 |
| Net Loss | $(1,484,802) | $(1,303,430) | $(31,391,281) |
| Loss Per Share (Basic/Diluted) | $(0.03) | $(0.02) | N/A |
| Cash and Cash Equivalents | $1,859,980 | $2,100,003 (End of Q1 2008) | N/A |
| Marketable Securities | $994,870 | $2,999,750 (Dec 31, 2008) | N/A |
| Total Assets | $3,404,617 | $4,113,989 (Dec 31, 2008) | N/A |
| Total Liabilities | $1,505,638 | $1,408,894 (Dec 31, 2008) | N/A |
| Operating Cash Flow | $(1,056,971) | $(1,186,702) | $(25,393,659) |
Material Changes vs. Prior Period
- Liquidity Improvement: Cash and cash equivalents increased significantly from $369,130 at December 31, 2008, to $1,859,980 at March 31, 2009. This was driven by a net cash inflow of $2,547,821 from investing activities, primarily due to the sale of marketable securities ($3,550,001 proceeds) offset by purchases ($1,001,345).
- Expense Fluctuations:
- General and Administrative (G&A): Increased 27.8% to $723,107, driven by a $36,500 NYSE Amex annual fee and higher payroll/legal costs.
- Research and Development (R&D): Decreased 7.4% to $721,926 due to reduced drug manufacturing costs and lower stock-based compensation.
- Interest Income: Decreased 92.9% to $7,609 due to lower cash balances and short-term investments compared to the prior year.
- Marketable Securities: The portfolio composition shifted from State authority auction rate bonds (Dec 2008) to Market Index Target Term Securities (Mar 2009), with a reduction in fair value from $2,999,750 to $994,870.
Outlook, Risks, and Management Commentary
- Liquidity Outlook: Management believes existing cash and marketable securities are sufficient to cover requirements through March 31, 2010. The company plans to reduce R&D and G&A expenses if necessary to conserve cash, which may slow clinical studies.
- Financing Needs: The company expects to spend a minimum of $3.4 million over the next 12 months ($1.2M on clinical trials, $2M on corporate expenses, $120k on rent). Additional financing up to $3.5 million may be required for full operational plans.
- Subsequent Event: On April 14, 2009, the company signed a non-binding Letter of Intent with the Health Policy and Research Foundation of California for up to $8.55 million to fund clinical development of Serdaxin. Receipt of funds is contingent on a definitive agreement.
- Legal Proceedings: On April 20, 2009, Amarex, LLC filed a lawsuit alleging breach of contract regarding a Phase II clinical study for Archexin, seeking $93,156 plus interest. The company intends to defend vigorously.
- Risk Factors: Significant risks include the need for additional capital, uncertainty of regulatory approvals, and the success of clinical trials. The company has an accumulated deficit of over $31 million.
Investor Verification Checklist
- Cash Runway: Verify if the projected cash burn rate aligns with the management's estimate of sufficiency through March 2010, given the lack of commercial revenue.
- Legal Contingency: Assess the potential financial impact of the Amarex, LLC lawsuit ($93,156 claim) and its effect on ongoing clinical trial relationships.
- Financing Contingency: Confirm the status of the non-binding Letter of Intent with the Health Policy and Research Foundation ($8.55M) and the likelihood of closing a definitive agreement.
- Investment Portfolio: Review the valuation and liquidity of the remaining $994,870 in marketable securities (Market Index Target Term Securities) and their maturity dates.
- Contractual Obligations: Review the $3.76 million in total value of R&D service agreements and the remaining unfunded commitments.